In oncologic epidemiology, this concerns the elevated risk of second primary malignancies in patients with a specific lymphoproliferative skin malignancy, with risk stratified by disease stage (tumor-stage or advanced-stage disease conferring higher risk), demonstrating markedly elevated relative risk for both solid and hematologic second cancers compared to a control population, with risk varying over time since diagnosis and by patient age. The proposed underlying mechanism is immune suppression secondary to the primary malignancy, situating the finding within the broader principle that certain cancers alter systemic immune surveillance, thereby increasing susceptibility to unrelated subsequent malignancies.
In oncologic epidemiology, this concerns the elevated risk of second primary malignancies in patients with a specific lymphoproliferative skin malignancy, with risk stratified by disease stage (tumor…